Diabetes Prevention Program Reauthorization Act of 2026

H.R. 10086, the Diabetes Prevention Program Reauthorization Act of 2026, amends the Public Health Service Act to reauthorize federal funding permissions for the National Diabetes Prevention Program.

This bill primarily affects: * **The National Diabetes Prevention Program**, which receives statutory authorization to continue receiving federal funds. * **Federal agencies and administrators** responsible for overseeing Public Health Service Act programs. The provided summary does not detail specific individual participant eligibility rules or restrictions.

The bill updates federal law by replacing outdated funding authorization language (which previously covered Fiscal Years 2010 through 2014) with new funding authorization levels for Fiscal Years 2027 through 2031.

The bill authorizes—but does not automatically mandate or spend—the following maximum appropriation amounts for the National Diabetes Prevention Program: * **Fiscal Year 2027:** $39,300,000 * **Fiscal Year 2028:** $44,300,000 * **Fiscal Year 2029:** $49,300,000 * **Fiscal Year 2030:** $54,300,000 * **Fiscal Year 2031:** $59,300,000 *Note: An authorization allows Congress to allocate funds up to these limits during the annual budgeting process, but it does not directly distribute money by itself.*

* The bill specifies authorized funding amounts only through Fiscal Year 2031. * The summary text does not mention any specific programmatic exceptions, taxes, fees, penalties, or statutory limitations beyond the authorized yearly budget caps.

This bill reauthorizes funding for the National Diabetes Prevention Program for five years (Fiscal Years 2027 to 2031), setting approved funding targets that start at $39.3 million in 2027 and increase annually to $59.3 million in 2031.